Strategic pivot Finch Therapeutics shifted away from CP101 Phase 3 in recurrent CDI to leverage its strong microbiome IP and broader asset portfolio, presenting an opportunity to discuss licensing, collaboration, or asset acquisition on its novel donor-derived and donor-independent microbiome platforms.

IP strength With an extensive IP estate of over 70 issued patents spanning donor-derived and donor-independent microbiome therapeutics, there is potential to pursue partnerships, licensing deals, or joint development agreements around its differentiated platforms and pre-clinical assets targeting ulcerative colitis, Crohn’s disease, and autism spectrum disorders.

Clinical assets CP101 has completed Phase 2 programs in recurrent CDI and ongoing collaboration for ulcerative colitis, suggesting opportunities to explore out-licensing, co-development, or in-licensing of CP101 data and related biomarkers for gut health indications.

Collaborative avenues Recent collaboration with Brigham and Women’s Hospital to study CP101 in ulcerative colitis signals openness to clinical partnerships and access to clinical sites, patient populations, and PK/safety data that can be leveraged for future studies or commercial programs.

Growth potential Public company status since 2021, mid-size team, and a funding base around $90M point to a scalable partnership model with larger biotech or pharma players seeking microbiome platforms, enabling strategic deals around commercialization rights, asset tiering, or milestone-driven collaborations.